Peterson M E, Becker D V
Department of Medicine, Cornell University Medical College, New York, NY 10021, USA.
J Am Vet Med Assoc. 1995 Dec 1;207(11):1422-8.
To evaluate a protocol for subcutaneous radioiodine treatment of cats with hyperthyroidism in which the dose was determined on the basis of severity of the cat's clinical signs, thyroid tumor size, and magnitude of the serum thyroxine (T4) concentration.
Prospective case series.
524 cats with hyperthyroidism.
A scoring system based on 3 factors (severity of clinical signs, size of the thyroid gland, and magnitude of the serum T4 concentration) was used to select the dose of radioiodine to be administered subcutaneously.
On the basis of the scoring system, 310 (59%) cats were treated with a low dose of radioiodine (< 3.5 mCi; median, 3.0 mCi), 158 (30%) were treated with a moderate dose (3.5 to 4.4 mCi; median, 4.0 mCi), and 56 (11%) were treated with a high dose (> or = 4.5 mCi; median, 5.0 mCi). At time of discharge from the hospital, serum T4 concentration was still high in 80 (15.3%) cats, but by 6 months after administration of radioiodine, the serum T4 concentration had decreased to within or below reference range in all but 8 (1.5%) cats with persistent hyperthyroidism. Many cats had low serum T4 concentrations at some time after radioiodine treatment, but only 11 (2.1%) cats developed clinical and clinicopathologic features of hypothyroidism and required supplementation with L-thyroxine. Thirteen (2.5%) cats had a relapse of hyperthyroidism 1.1 to 6.5 years after initial radioiodine treatment. Overall, the response to treatment was considered good in 94.2% of the cats. Median survival time in the cats was 2.0 years; the percentage of cats alive after 1, 2, and 3 years of treatment was 89, 72, and 52%, respectively.
Results of the study suggest that this method of dose estimation works well and that subcutaneous administration of radioiodine provides a safe and effective means of treating hyperthyroidism in cats.
评估一种用于皮下注射放射性碘治疗猫甲状腺功能亢进的方案，该方案根据猫的临床症状严重程度、甲状腺肿瘤大小和血清甲状腺素（T4）浓度来确定剂量。
前瞻性病例系列。
524只患有甲状腺功能亢进的猫。
基于3个因素（临床症状严重程度、甲状腺大小和血清T4浓度）的评分系统用于选择皮下注射放射性碘的剂量。
根据评分系统，310只（59%）猫接受低剂量放射性碘治疗（<3.5毫居里；中位数为3.0毫居里），158只（30%）接受中等剂量治疗（3.5至4.4毫居里；中位数为4.0毫居里），56只（11%）接受高剂量治疗（≥4.5毫居里；中位数为5.0毫居里）。出院时，80只（15.3%）猫的血清T4浓度仍较高，但在注射放射性碘6个月后，除8只（1.5%）持续甲状腺功能亢进的猫外，所有猫的血清T4浓度均降至参考范围内或以下。许多猫在放射性碘治疗后的某个时间血清T4浓度较低，但只有11只（2.1%）猫出现甲状腺功能减退的临床和临床病理特征并需要补充左旋甲状腺素。13只（2.5%）猫在首次放射性碘治疗后1.1至6.5年出现甲状腺功能亢进复发。总体而言，94.2%的猫对治疗反应良好。猫的中位生存时间为2.0年；治疗1、2和3年后存活的猫的百分比分别为89%、72%和52%。
研究结果表明，这种剂量估计方法效果良好，皮下注射放射性碘为治疗猫甲状腺功能亢进提供了一种安全有效的方法。
